# NCT04613596 (NCT04613596)

> Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04613596
- Phase: PHASE2, PHASE3
- Status: RECRUITING
- Sponsor: Mirati Therapeutics Inc.
- Conditions: Advanced Non-Small Cell Lung Cancer; Metastatic Non-Small Cell Lung Cancer
- Interventions: Adagrasib; Adagrasib; Adagrasib; Adagrasib; Pembrolizumab
- Enrollment: 626
- Primary outcome: Phase 2: To evaluate the efficacy of Adagrasib monotherapy and in combination with pembrolizumab administered to patients having advanced/metastatic NSCLC.
- Primary outcome: Phase 3: To compare efficacy of Adagrasib in combination with pembrolizumab versus pembrolizumab

## Commentary we found

- Podcasts: 2
- YouTube: 1
- X threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct04613596